Single‐chain pro‐urokinase is an inactive proenzyme form of human urokinase (urinary plasminogen activator) with a Mr of 50,000 which is converted to the active two‐chain form by catalytic amounts of plasmin. It is used for thrombolytic therapy of acute myocardial infarction and acute ischemic stroke. We have isolated single‐stranded DNA molecules with significantly increased binding affinity for human pro‐urokinase by SELEX (systematic evolution of ligands by exponential enrichment) procedure from a pool of 1015 molecules containing 24 randomized positions which are flanked by defined regions. ssDNA from this library was hybridized with helper «fixture», thus allowing the central random chain to fold into complex three‐dimentional shapes. Sequencing data from pro‐urokinase aptamers obtained after 12 selection cycles displayed a highly conserved 12–14 base region.
[1]
J. Szostak,et al.
Selection in vitro of single-stranded DNA molecules that fold into specific ligand-binding structures
,
1992,
Nature.
[2]
S. Moore,et al.
Ribonuclease inhibitor from human placenta. Purification and properties.
,
1977,
The Journal of biological chemistry.
[3]
R. Breaker.
DNA aptamers and DNA enzymes.
,
1997,
Current opinion in chemical biology.
[4]
E. Vermaas,et al.
Selection of single-stranded DNA molecules that bind and inhibit human thrombin
,
1992,
Nature.
[5]
H. Schluesener,et al.
Systematic Evolution of a DNA Aptamer Binding to Rat Brain Tumor Microvessels
,
2001,
The Journal of Biological Chemistry.